This story originally written by Matt Rosoff at CITEworld. Sign up for our free newsletter here.
If there was any doubt, the latest smartphone market share numbers�from IDC�make it crystal clear that it's a two-horse race. IT and developers should plan accordingly and ignore all talk of third platforms for the time being.
Together, Google� (NASDAQ: GOOG ) Android and Apple� (NASDAQ: AAPL ) iOS made up 93.8% of all smartphone shipments in 2013, up from 87.7% in 2012. In the fourth quarter of last year, the two main platforms made up 95.7% of smartphone shipments, up from 91.2%. In other words, the two main platforms are getting more dominant, not less.�
Most of the takeaway comes from BlackBerry� (NASDAQ: BBRY ) and from "other" platforms, such as Symbian. But the outlook also looks bleak for Microsoft's (NASDAQ: MSFT ) Windows Phone. Absolute shipments nearly doubled from 17.5 million to 33.4 million between 2012 and 2013. That's nice. But the overall smartphone market is growing so fast, that only amounted to a slight gain in market share, from 2.4% to 3.3%.
5 Best Biotech Stocks To Invest In Right Now: Intellipharmaceutics International Inc.(IPCI)
Intellipharmaceutics International Inc. engages in the research, development, and manufacture of novel or generic controlled and targeted release oral solid dosage drugs. The company?s patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of various existing and new pharmaceuticals. It has a pipeline of products in various stages of development in therapeutic areas, including neurology, cardiovascular, and gastrointestinal tract, pain, and infection. The company?s lead generic product under development includes generic Focalin XR (dexmethylphenidate hydrochloride), an extended-release capsule for the treatment of attention deficit hyperactivity disorder. Intellipharmaceutics has a license and commercialization agreement with Par Pharmaceutical, Inc. for the development and commercialization of generic Focalin XR. The company also has five generic products filed with the FDA, including a gene ric of Effexor XR (venlafaxine hydrochloride), an extended-release capsule for depression; Protonix (pantoprazole sodium), a delayed-release tablet for conditions associated with gastroesophageal disease; Glucophage XR (metformin hydrochloride), an extended-release tablet for managing type 2 diabetes; Seroquel XR (quetiapine fumarate), an extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorder; and Lamictal XR (lamotrigine), an extended-release tablet for the treatment of anti-convulsant for epilepsy. Its lead non-generic product under development is Rexista (oxycodone), an abuse- and alcohol-deterrent controlled-release oral oxycodone hydrochloride formulation for the relief of pain. The company also has a under late stage development product, such as Coreg CR (carvedilol phosphate), an extended-release capsule for hypertension and heart conditions. IntelliPharmaCeutics International Inc. was founded in 1998 and is based i n Toronto, Canada.
Advisors' Opinion:- [By Roberto Pedone]
A pharmaceutical player that's starting to trend within range of triggering a big breakout trade is IntelliPharmaCeutics (IPCI), which specializing in the research, development and manufacture of generic controlled-release and targeted-release oral solid dosage drugs. This stock has been on fire over the last three months, with shares up a whopping 99%.
If you take a look at the chart for IntelliPharmaCeutics, you'll notice that this stock has been uptrending a bit over the last few weeks, with shares moving higher from its low f $3.12 to its recent high of $4.37 a share. During that uptrend, shares of IPCI have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of IPCI within range of triggering a big breakout trade above some key overhead resistance levels.
Traders should now look for long-biased trades in IPCI if it manages to break out some near-term overhead resistance levels at $4.37 to $4.62 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.31 million shares. If that breakout triggers soon, then IPCI will set up to re-test or possibly take out its 52-week high at $6.46 a share.
Traders can look to buy IPCI off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $3.36 or at its 50-day moving average of $3.13 a share. One could also buy IPCI off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Hot Industrial Disributor Companies To Own In Right Now: Kohl's Corporation(KSS)
Kohl?s Corporation operates department stores in the United States. The company?s stores offer private and exclusive, as well as national branded apparel, footwear, and accessories for women, men, and children; soft home products, such as sheets and pillows; and housewares primarily to middle-income customers. As of January 29, 2011, it operated 1,089 stores in 49 states. The company also offers on-line shopping on its Web site at Kohls.com. Kohl?s Corporation was founded in 1962 and is headquartered in Menomonee Falls, Wisconsin.
Advisors' Opinion:- [By WWW.DAILYFINANCE.COM]
www.fossil.com From the world's largest retailer stepping up with fresh financials to a maker of fashionable timepieces proving that it can still grow in this unwelcome climate for watchmakers, here are some of the things that will help shape the week that lies ahead on Wall Street. Monday -- Sounds Good DTS (DTSI) has carved a cozy living providing sound-enhancing technology in Blu-ray players, video game consoles and other devices. Despite its success, DTS is trading a lot closer to its 52-week low than its 52-week high. One thing holding it back is that it has failed to impress the market with its quarterly financials. It's coming off back-to-back quarters of falling short of Wall Street's profit expectations. It's against this setting that DTS will step up after Monday's market close to deliver its latest results. Will the streak of disappointment stretch to three quarters, or is DTS finally going to put out a report that looks as good as its audio technology sounds? We will know soon. Tuesday -- Fossil Fuel Fossil (FOSL) may seem to be toiling away in an industry worthy of its name. Aren't wristwatches dinosaurs? Who wears watches anymore when we have smartwatches to tell us the time. Folks with active lifestyles are saving their wrists for fitness bracelets. Well, Fossil is growing just nicely in this environment, thank you very much. When the trendy watchmaker reports on Tuesday analysts see revenue climbing 13 percent. They see top-line growth of 10 percent for all of 2014. Fossil's profitability isn't expected to clock in as nicely, but unlike DTS,we've seen Fossil blow Wall Street's profit targets away consistently over the past year. Wednesday -- Press Hard CafePress (PRSS) has been a disappointment for investors since going public at $19 two years ago. The stock opened higher on its first day of trading, but it's been mostly downhill for the shares, which now fetch less than a third of the initial public offering price. CafePress was hoping
Hot Industrial Disributor Companies To Own In Right Now: ONYX Pharmaceuticals Inc.(ONXX)
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. The company, through its collaboration agreement with Bayer HealthCare Pharmaceuticals, Inc., develops and markets Nexavar (sorafenib) tablet, a multiple kinase inhibitor for the treatment of liver cancer and advanced kidney cancer. It is also conducting Phase III clinical trial on Nexavar for the treatment of kidney, liver, lung, thyroid, breast, and non-small cell lung cancers; clinical trials on carfilzomib, a proteasome inhibitor for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors; and Phase Ib/II clinical trial on Oprozomib, an oral proteasome inhibitor. In addition, Onyx Pharmaceuticals, Inc. is developing ONX 0914, an immunoproteasome inhibitor, which is in preclinical stage for the treatment of autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease, and lupus. Further, the company, through its collaboration agreement with Bayer HealthCare Pharmaceuticals, Inc., is conducting clinical trials on Regorafenib, a multi-kinase inhibitor to treat metastatic colorectal cancer and gastrointestinal stromal tumors. It has a collaboration agreement with Warner-Lambert Company to discover and commercialize small molecule drugs that restore control of or intervene in the misregulated cell cycle in tumor cells. The company also has development and license agreements with BTG International Limited for the development and commercialization of ONX 0801, a novel targeted oncology compound; and Ono Pharmaceutical Co., Ltd. to develop and commercialize carfilzomib and Oprozomib for oncology indications in Japan. Onyx Pharmaceuticals, Inc. was founded in 1992 and is headquartered in South San Francisco, California.
Advisors' Opinion:- [By Keith Speights]
Also, more studies including Revlimid in first-line treatment of multiple myeloma are likely on the way. In April, results from a phase 1/2 trial with Onyx Pharmaceuticals' (NASDAQ: ONXX ) Kyprolis in combination with Revlimid and low-dose dexamethasone� showed promising results. Onyx received Food and Drug Administration approval for Kyprolis as a third-line treatment for multiple myeloma in July 2012.�Kyprolis is technically a rival to Celgene's Pomalyst, but there's room for both drugs to be successful.
- [By Jon C. Ogg]
Amgen Inc. (NASDAQ: AMGN)�wants to regain its status as the largest publicly traded biotech in the U.S. The company formalized a buyout of cancer drug maker Onyx Pharmaceuticals Inc. (NASDAQ: ONXX)�for about $10.4 billion over the weekend. Amgen is seeking to reinitiate some growth and to bolster its pipeline, and we cannot help but point out that Onyx is one of the few companies we identified as one that aims to double its sales and then some in the next couple to few years.
- [By Sean Williams]
Tivozanib is an oral, once-daily treatment for metastatic renal cell carcinoma that works by blocking three VEGR-receptors that are critical for blood vessel growth development for solid renal cell tumors, and is being targeted as a first-line treatment. In trials, AVEO and its partner Astellas Pharma went head-to-head against Onyx Pharmaceuticals' (NASDAQ: ONXX ) Nexavar and delivered good, but not groundbreaking, results. In its TIVO-1 study, released last year, Tivozanib met its primary progress-free survival endpoint and delivered a median PFS of 11.9 months compared with the median PFS of just 9.1 months for Nexavar. The difference was even more pronounced in treatment-naive patients where the PFS difference grew to 12.7 months as compared to 9.1 months for Nexavar. However, overall survival rates for AVEO's drug actually were slightly�lower than Nexavar over the course of the study. �
Hot Industrial Disributor Companies To Own In Right Now: Granite Construction Inc (GVA)
Granite Construction Incorporated (Granite), incorporated on January 24, 1990, is a diversified heavy civil contractors and construction materials producers in the United States. The Company operates in four segments: Construction, Large Project Construction, Construction Materials and Real Estate. The Company operates nationwide, serving both public and private sector clients. Within the public sector, it primarily concentrates on heavy-civil infrastructure projects, including the construction of roads, highways, mass transit facilities, airport infrastructure, bridges, dams and other infrastructure related projects. Within the private sector, it performs site preparation and infrastructure services for residential development, commercial and industrial buildings, and other facilities. The Company owns and leases substantial aggregate reserves and own a number of construction materials processing plants. It also has contractor-owned heavy construction equipment fleets in the United States. In December 2012, it purchased 100% interest of Kenny Construction Company (Kenny).
Construction
Revenue from its Construction segment was approximately 47% of its total revenue during the year ended December 31, 2012. Revenue from its Construction segment is derived from both public and private sector clients. The Construction segment performs various heavy civil construction projects with a large portion of the work focused on new construction and improvement of streets, roads, highways, bridges, site work and other infrastructure projects. These are typically bid-build projects completed within two years.
Large Project Construction
Revenue from its Large Project Construction segment was 41.4% of its total revenue in 2012. The Large Project Construction segment focuses on large, complex infrastructure projects, which typically have a longer duration than its Construction segment work. These projects include major highways, mass transit facilities, bridges, tunn! els, waterway locks and dams, pipelines, canals and airport infrastructure. This segment primarily includes bid-build, design-build and construction management/general contractor contracts. It participates in joint ventures with other construction companies mainly on projects in its Large Project Construction segment. Joint ventures are typically used for large, technically complex projects, including design/build projects, where it is desirable to share risk and resources. Joint venture partners typically provide independently prepared estimates, shared financing and equipment and often bring local knowledge and expertise.
The Company also utilizes the design/build and construction management/general contract methods of project delivery. Under the construction management/general contract method of delivery, it contracts with owners to manage the design phase of the contract with the understanding that it will negotiate a contract on the construction phase when the design nears completion. Revenue from design/build and construction management/general contract projects represented 74.5% of Large Project Construction revenue in 2012.
Construction Materials
Revenue from its Construction Materials segment was 11.1% of its total revenue in 2012. The Construction Materials segment mines and processes aggregates and operates plants that produce construction materials for internal use and for sale to third parties. It has aggregate reserves that it has acquired by ownership in fee or through long-term leases. Aggregate products used in its construction projects represented approximately 42.7% of its tons sold during 2012.
Real Estate
Granite Land Company (GLC) is an investor in a diversified portfolio of land assets and provides real estate services for other Granite operations. GLC�� investment portfolio consists of residential, as well as retail and office site development projects for sale to home and commercial property developers. The range! of its i! nvolvement in an individual project may vary from passive investment to management of land use rights, development, construction, leasing and eventual sale of the project. Generally, GLC has teamed with partners who have local knowledge and expertise in the development of each property. GLC�� investments are located in Washington, California and Texas. Revenue from GLC was 0.2% of its total revenue in 2012.
Advisors' Opinion:- [By Wallace Witkowski]
Some of the companies most dependent on government for revenue are Harris Corp. (HRS) �with 80% of revenue government-derived; Granite Construction Inc. (GVA) �with 58%; Flir Systems Inc. (FLIR) �with 54%; and Waste Management Inc. (WM) � and Republic Services Inc. (RSG) �both with 50%, according to Goldman Sachs.
- [By Louis Navellier]
If we look at the sector using Portfolio Grader, we see that many of the big names in the group like Flour (FLR), Granite Construction (GVA) and KBR incorporated (KBR) are rated ��ell.��The anticipated spending for both government and private industry simply hasn�� materialized, and the companies are not seeing revenue or profit growth.
Hot Industrial Disributor Companies To Own In Right Now: ATA Inc.(ATAI)
ATA Inc., through its subsidiaries, provides computer-based testing services in the People?s Republic of China. It offers services for the creation and delivery of computer-based tests utilizing its test delivery platform, proprietary testing technologies, and testing services; and provides logistical support services relating to test administration. The company?s computer-based testing services are used for professional licensure and certification tests in various industries, including information technology (IT) services, banking, securities, teaching, and insurance. Its e-testing platform integrates various aspects of the test delivery process for computer-based tests ranging from test form compilation to test scoring, and results analysis. ATA also provides career-oriented educational services, such as single course programs, degree major course programs, and pre-occupational training programs focusing on preparing students to pass IT and other vocational certification tests; test preparation and training programs and services to test candidates preparing to take professional certification tests in securities, futures, banking, insurance and teaching industries; online test preparation and training platform for the securities and banking industries; and test preparation software for the teaching industry. In addition, the company offers HR select employee assessment solution, an online system that utilizes its proprietary software and an inventory of test titles to help employers improve the efficiency and accuracy of their employee recruitment process. As of March 31, 2010, it had contractual relationships with 1,988 ATA authorized test centers. The company serves Chinese governmental agencies, professional associations, IT vendors, and Chinese educational institutions, as well as individual test preparation services. ATA Inc. was founded in 1999 and is based in Beijing, the People?s Republic of China.
Advisors' Opinion:- [By Jake L'Ecuyer]
Leading and Lagging Sectors
Industrials stocks gained Friday, with ATA (NASDAQ: ATAI) leading advancers. Meanwhile, gainers in the sector included Plug Power (NASDAQ: PLUG), with shares up 22 percent, and Korn/Ferry International (KFY), with shares up 12 percent. In trading on Friday, basic materials shares were relative laggards, down on the day by about 1.36 percent. - [By Jake L'Ecuyer]
Leading and Lagging Sectors
Industrials stocks gained Friday, with ATA (NASDAQ: ATAI) leading advancers. Meanwhile, gainers in the sector included Plug Power (NASDAQ: PLUG), with shares up 22 percent, and Korn/Ferry International (KFY), with shares up 12 percent. In trading on Friday, basic materials shares were relative laggards, down on the day by about 1.36 percent.
Hot Industrial Disributor Companies To Own In Right Now: Aerosonic Corporation(AIM)
Aerosonic Corporation, together with its subsidiaries, engages in the design, manufacture, and sale of aircraft instruments worldwide. It offers mechanical and digital altimeters, airspeed indicators, rate of climb indicators, microprocessor controlled air data test sets, and other flight instruments. The company also produces mechanical and electro-mechanical cockpit instruments, angle of attack stall warning systems, digital cockpit instruments, integrated flight display systems, aircraft sensors and monitoring systems, and integrated multifunction probes, such as integrated air data sensors. It markets its products to manufacturers of corporate and private jets, contractors of military jets, the United States government, and private aircraft owners. The company sells its products directly through its sales personnel, as well as through distributors and commissioned sales representatives who resell to aircraft operators. Aerosonic Corporation was founded in 1953 and is b ased in Clearwater, Florida.
Advisors' Opinion:- [By Katia Dmitrieva]
Aimia (AIM) Inc.�� decision to move its Aeroplan reward-partnership to Toronto-Dominion (TD) Bank is a blow to Canadian Imperial Bank of Commerce, which stands to lose customers and as much as C$3 billion ($2.9 billion) in credit-card balances.